Misplaced Pages

SB269652

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Dopamine receptor modulator Pharmaceutical compound
SB269652
Clinical data
Other namesSB-269652; SB-269,652
Drug classDopamine D2 and D3 receptor negative allosteric modulator
Identifiers
IUPAC name
  • N-cyclohexyl]-1H-indole-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC27H30N4O
Molar mass426.564 g·mol
3D model (JSmol)
SMILES
  • C1CC(CCC1CCN2CCC3=C(C2)C=C(C=C3)C#N)NC(=O)C4=CC5=CC=CC=C5N4
InChI
  • InChI=1S/C27H30N4O/c28-17-20-5-8-21-12-14-31(18-23(21)15-20)13-11-19-6-9-24(10-7-19)29-27(32)26-16-22-3-1-2-4-25(22)30-26/h1-5,8,15-16,19,24,30H,6-7,9-14,18H2,(H,29,32)
  • Key:JGLGOAQPUQITLD-UHFFFAOYSA-N

SB269652 is an experimental dopamine D2 and D3 receptor negative allosteric modulator. It is of interest in the potential development of novel antipsychotics for treatment of schizophrenia with reduced side effects, such as extrapyramidal symptoms. The drug is described as a dual orthosteric and allosteric (i.e., bitopic) modulator of the dopamine D2 and D3 receptors, as an atypical allosteric modulator of these receptors, and as specifically targeting D2–D3 receptor dimers. SB269652 was first described in the scientific literature by 1999. It was originally thought to act purely as an antagonist of the dopamine D2 and D3 receptors, but was serendipitously found to be a negative allosteric modulator of these receptors in 2010. It was the first dopamine D2 and D3 receptor negative allosteric modulator to be discovered. More potent analogues of SB269652 have been developed.

References

  1. ^ Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M (June 2017). "The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs". Mol Pharmacol. 91 (6): 586–594. doi:10.1124/mol.116.107607. PMC 5438131. PMID 28265019.
  2. ^ Fasciani I, Petragnano F, Aloisi G, Marampon F, Carli M, Scarselli M, Maggio R, Rossi M (November 2020). "Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics". Pharmaceuticals (Basel). 13 (11): 388. doi:10.3390/ph13110388. PMC 7696972. PMID 33202534.
  3. Taylor, S. G., Riley, G., Hunter, A. J., Stemp, G., Routledge, C., Hagan, J. J., & Reavill, C. (1999). SB-269652 is a selective D3 receptor antagonist in vitro and in vivo. European Neuropsychopharmacology, (9), 266. https://scholar.google.com/scholar?cluster=9009628132294457655
  4. Taylor, S. G., Riley, G., Hunter, A. J., Stemp, G., & Routledge, C. (1999). A selective dopamine D 3 receptor antagonist, SB-269652, shows functional selectivity for D 3 receptors in vivo. Monitoring molecules in neuroscience. SUNY at Stony Brook, New York, 254-255. https://scholar.google.com/scholar?cluster=7754123302347796269
  5. Kopinathan A, Draper-Joyce C, Szabo M, Christopoulos A, Scammells PJ, Lane JR, Capuano B (January 2019). "Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D2 Receptor". J Med Chem. 62 (1): 371–377. doi:10.1021/acs.jmedchem.8b00192. PMID 29890071.
Dopamine receptor modulators
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: